Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $57.8571.

Several research analysts recently commented on the stock. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wells Fargo & Company cut their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Piper Sandler restated an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd.

Omnicell Stock Performance

Shares of OMCL opened at $32.43 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell has a twelve month low of $29.06 and a twelve month high of $55.00. The firm’s 50 day moving average price is $36.95 and its two-hundred day moving average price is $38.71. The firm has a market cap of $1.47 billion, a P/E ratio of 38.61, a PEG ratio of 0.81 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter in the prior year, the company earned $0.45 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts forecast that Omnicell will post 1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC grew its holdings in Omnicell by 80.8% in the second quarter. Squarepoint Ops LLC now owns 120,419 shares of the company’s stock worth $5,000,000 after purchasing an additional 53,807 shares during the period. Nykredit A S bought a new stake in shares of Omnicell during the second quarter worth about $26,000. Corient Private Wealth LP increased its position in shares of Omnicell by 46.7% during the second quarter. Corient Private Wealth LP now owns 62,809 shares of the company’s stock worth $2,608,000 after acquiring an additional 20,000 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Omnicell in the 2nd quarter worth about $340,000. Finally, Moore Capital Management LP bought a new position in Omnicell during the 2nd quarter valued at $3,644,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.